| Patent application number | Description | Published |
|---|
| 20080274144 | HCV E1 COMPRISING SPECIFIC DISULFIDE BRIDGES - The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof. | 11-06-2008 |
| 20090104207 | Hepatitis C Virus Neutralizing Antibodies - The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies. | 04-23-2009 |
| 20090311248 | Hepatitis C Virus Neutralizing Antibodies - The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies. | 12-17-2009 |
| 20100099613 | PEPTIDES FOR INDUCING A CTL AND/OR HTL RESPONSE TO HEPATITIS C VIRUS - The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients. | 04-22-2010 |
| 20110110974 | METHODS AND KITS FOR INDUCING A CTL RESPONSE USING A PRIME BOOST REGIMEN - The present invention relates to the generation of a T cell response against a target antigen using a polypeptide comprising a polyepitope construct as a priming composition in a prime boostregimen. | 05-12-2011 |
| 20110129489 | METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR - The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern. | 06-02-2011 |
| 20110182897 | AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 07-28-2011 |
| 20110311515 | PULMONARY ADMINISTRATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND CONSTRUCTS THEREOF - The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route. | 12-22-2011 |
